EXPERT GROUP TO REVIEW EVIDENCE FOR USE OF MEDICAL CANNABIS FOR EMPLOYER PLANS

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) — Today, Reformulary Group, Canada’s leading, independent drug plan management company, announced its Cannabis Formulary Committee, which will review the best available evidence for medical cannabis and provide expert opinions and criteria for its use in specific indications. The Cannabis Formulary Committee will recommend specific medical uses and develop criteria for appropriate use, lines of therapy, specific strains, form, grams per indication, mode of consumption and quantity limits. MORE>>